USA Today Examines Possible Reasons For Five-Year Low Of FDA Drug Approval Rate
Some industry analysts say FDA is being more careful in granting approvals "after drawing criticism in recent years for approving some drugs whose risks were found to outweigh their benefits after they went on the market," such as Vioxx and Bextra, USA Today reports. In addition, Linda Bannister, a health care analyst at Edward Jones, said she believes FDA may be less likely to approve medications that do not show a clear benefit over older versions of similar drugs and that might carry unknown risks. Meanwhile, Ira Loss of the research firm Washington Analysis said that the industry's "research drought" has led to weakened drug applications and fewer approvals. Loss said the number of new drug discoveries peaked in the mid-1990s and then "petered out."
FDA spokesperson Christopher DeFrancesco said the agency's approval standards for new drug submissions have remained the same, adding that the rate of approvals to submissions has stayed consistent at about 80% between 1997 and 2005 (USA Today, 2/4).
Reprinted with kind permission from http://www.kaisernetwork.org. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at http://www.kaisernetwork.org/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation© 2005 Advisory Board Company and Kaiser Family Foundation. All rights reserved.
View drug information on Bextra; Vioxx.
USA Today examineazã motivele posibile pentru cinci ani a scãzut rata de aprobare FDA de droguri - USA Today Examines Possible Reasons For Five-Year Low Of FDA Drug Approval Rate - articole medicale engleza - startsanatate